United Nations Security Council Resolution 29

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

Retrieved on: 
Wednesday, June 28, 2023
United Nations Security Council Resolution 29, Euronext, CET, Television, Cellectis, ABQ BioPark Aquarium

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Key Points: 
  • NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, hold its annual general meeting on June 27, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
  • At the meeting, during which more than 72% of shares were exercised, Resolutions 1 through 28 were adopted and resolution 29 was rejected, according to the management recommendations.
  • The detailed results of the vote and the resolutions are available on the company’s website:

ERYTECH announces that Akkadian is continuing its attempt at destabilization with the filing of a new lawsuit

Retrieved on: 
Tuesday, June 20, 2023
AMF, Annual general meeting, Euronext Paris, United Nations Security Council Resolution 29, Mass meeting, Failure, Commercial code, Partner, Pherecydes, Hearing

Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners.

Key Points: 
  • Cambridge, MA (U.S.) and Lyon (France), June 20, 2023 – ERYTECH Pharma (Euronext Paris and Nasdaq: ERYP) announces the filing of a new lawsuit by Akkadian Partners.
  • Despite the rejection by the President of the Lyon Commercial Court of Akkadian Partners' request to postpone the General Meeting's vote on the proposed merger, Akkadian has initiated new legal proceedings with the clear aim of continuing its attempt to destabilize Erytech.
  • As part of this new procedure, the first hearing of which will take place after the vote on the merger, Akkadian Partners is requesting the cancellation of the capital increase of May 15, 2023.
  • Erytech is confident of the outcome of this unfounded procedure, which appears bound to failure.

ERYTECH Provides Update on the Announced Combination with PHERECYDES

Retrieved on: 
Monday, May 15, 2023
Commercial Court, Tripura Merger Agreement, United Nations Security Council Resolution 29, Commercial code, Proposed merger of Publicis and Omnicom, Contribution, AMF, Holding company, Security (finance), Management

In relation with the announced merger of PHERECYDES into ERYTECH (the “Proposed Merger”), ERYTECH and PHERECYDES entered into a merger agreement on May 15, 2023, pursuant to which PHERECYDES will be merged into ERYTECH and PHERECYDES shareholders will receive 15 new ERYTECH shares for every 4 PHERECYDES shares they own (the “Merger Agreement”).

Key Points: 
  • In relation with the announced merger of PHERECYDES into ERYTECH (the “Proposed Merger”), ERYTECH and PHERECYDES entered into a merger agreement on May 15, 2023, pursuant to which PHERECYDES will be merged into ERYTECH and PHERECYDES shareholders will receive 15 new ERYTECH shares for every 4 PHERECYDES shares they own (the “Merger Agreement”).
  • The annual general meetings of ERYTECH and PHERECYDES shareholders will be called upon to vote on the Proposed Merger on June 23, 2023.
  • The Proposed Merger is expected to close shortly after the approval by both ERYTECH and PHERECYDES shareholders.
  • Guy Rigaud, of 827,132 PHERECYDES shares to ERYTECH in consideration of 3,101,745 newly issued ERYTECH shares (the “Contribution”).